Search Results 7791-7800 of 36503 for oral

1. A Study of AMG 757 in Participants With Neuroendocrine Prostate Cancer - Mayo Clinic

   Active infection requiring oral or IV antimicrobials for management within 7 days of first dose tarlatamab. Exclusion of hepatitis infection based on the ...

2. A Study to Evaluate Gemcitabine and MK-3475 (Pembrolizumab) to Treat Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer - Mayo Clinic

   Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus ...

3. A Study to Evaluate Pembrolizumab, Ixazomib Citrate, and Dexamethasone to Treat Participants with Relapsed Multiple Myeloma - Mayo Clinic

   Known gastrointestinal (GI) disease or GI procedure that could interfere with the oral absorption or tolerance of ixazomib including difficulty swallowing.

4. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   Known GI disease or GI procedure that could interfere with the oral absorption or tolerance of CB-839 HCl (telaglenastat) including difficulty swallowing ...

5. Outcomes Database To ProspectivelY ASSEss The Changing TherapY Landscape In Renal Cell Carcinoma (ODYSSEY RCC) - Mayo Clinic

   Non-cytotoxic oral agents for adjuvant or maintenance therapy of other cancers are permitted. * Patients who are not intending to undergo follow up care at ...

6. Cisplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery - Mayo Clinic

   NOTE: PET-CT scans are allowed provided the CT portion of the exam is equivalent to a diagnostic CT scan and includes both oral and IV contrast. Patients ...

7. Head and neck cancers - Doctors and departments - Mayo Clinic

   Oral and Maxillofacial Surgery · Otolaryngology (ENT)/Head and Neck Surgery · Pediatric Hematology/Oncology · Pediatric Otolaryngology · Pediatrics · Physical ...

8. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy Or Plus Camizestrant In HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, Or PALB2m Advanced Breast Cancer - Mayo Clinic

   Disease progression ≤ 1 year (365 days) from the last dose of an oral SERD including camizestrant. Note: Other protocol defined Inclusion/Exclusion ...

9. Spatz3 Adjustable Balloon System® (Spatz3) Post Approval Study - Mayo Clinic

   Acceptable birth control methods are limited to hormonal contraceptives (oral, flexible vaginal ring, skin patch, injection), diaphragms, IUDs, condoms with or ...

10. Tongue cancer - Doctors and departments - Mayo Clinic

    Improving and adapting existing robotic surgery systems for use on tumors of the tongue. Investigating tumor growth factors for oral cancer. Evaluating new ...